Posted by Michael Wonder on 03 Jun 2020
EMA weighs COVID-19 data transparency, not ready to resume full clinical data publication
1 June 2020 - In a response to officials at Germany’s IQWiG and the Cochrane Collaboration, EMA Executive Director Guido Rasi said the agency is trying to figure out how to be transparent with regard to clinical trial data for products it reviews to treat or prevent coronavirus disease (COVID-19).
After spending years implanting its policy for proactively publishing clinical data for products submitted to the agency for review, EMA suspended its publication efforts in August 2018 to focus on its relocation from London to Amsterdam as part of its Brexit business continuity plan.
